Eli Lilly (LLY), the maker of the blockbuster weight-loss drug Zepbound, announced Wednesday that it plans to invest $27 ...

Whatever you think of Donald Trump’s tariff policies, one fact stands out: companies are looking to invest more in the United ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Back in December, I argued why I was ready to upgrade the stock of the embattled weight loss drugs leader Eli Lilly and Company ... and competitive upheavals isn't just expected, but also pivotal.

While having an accrual ratio above zero is of little concern, we do think it's worth noting when ... to lower profit or less profit growth. Eli Lilly has an accrual ratio of 0.25 for the year ...

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » For years, Eli Lilly has been generating solid growth ...

It's hard to argue with the kinds of results Eli Lilly (NYSE: LLY ... Both medicines are in phase 3 studies, but not just as weight loss management products: They're being developed as potential ...

These are some of the areas where Eli Lilly, flush with cash from ... delivering to other tissues, it's not just the genetic medicine, it's how do you package it? How do you target it with ...

The move came just ... programs do not systematically cover people living with obesity for medical care - this needs to change," said Patrik Jonsson, executive vice president of Eli Lilly and ...

We recently published a list of Jim Cramer Discusses These 13 Stocks & Criticizes Billionaires. In this article, we are going ...